Drug-induced Hypotension Clinical Trial
Official title:
Observational Study of the Safety and Efficacy of Nucleoside Reverse Transcriptase Inhibitor Backbones With Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in Antiretroviral Therapy-Naive Patients and First-Switch Subjects
Hypotension does not occur with Maraviroc at a dose of 600 mg/day
A qualitative description of orthostatic hypotension in patients receiving once daily Maraviroc at 600 mg with Epzicom measured by a validated questionnaire ;
Observational Model: Case-Only, Time Perspective: Retrospective